# OnCo record setmelanotide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/setmelanotide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "setmelanotide" ;
  schema:name "Setmelanotide"@en ;
  schema:alternateName "RM-493"@en, "Imcivree" ;
  schema:description "Setmelanotide is a daily injection that switches back on the brain's fullness signal. Approved for rare genetic causes of obesity, it is being tested for the relentless weight gain that follows damage to the hypothalamus from craniopharyngioma surgery or radiotherapy."@en ;
  schema:url <https://onco.cc/drugs/setmelanotide/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Setmelanotide> ;
  schema:citation <https://en.wikipedia.org/wiki/Setmelanotide> ;
  onco:status "approved" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Subcutaneous melanocortin-4 receptor agonist" ;
  onco:approval "US 2020: Chronic weight management in obesity due to POMC, PCSK1 or LEPR deficiency" ;
  onco:cancers <https://onco.cc/cancers/craniopharyngioma/> ;
  onco:companies <https://onco.cc/companies/rhythm-pharmaceuticals/> .